EBMT 2021 | HRQoL and frail patients with R/R multiple myeloma
Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, gives an overview of her talk at EBMT 2021 on health-related quality-of-life (HRQoL) for frail patients with relapsed/refractory (R/R) multiple myeloma. Dr Mateos describes challenges associated with treating frail patients with R/R multiple myeloma, such as lenalidomide-refractoriness, and emphasizes the need to balance efficacy, tolerability and HRQoL. Dr Mateos also outlines potential therapies for this group of patients, highlighting pomalidomide plus dexamethasone with elotuzumab, bortezomib or isatuximab. A post-hoc analysis of the ICARIA-MM study (NCT02990338), conducted according to the frailty score, demonstrated that isatuximab plus pomalidomide and dexamethasone was equally effective in fit and frail patients with R/R multiple myeloma. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
